Kazia Therapeutics Ltd ADR (KZIA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $63.99M
Last updated: Nov 17, 2026 at 4:24 PM ET
Kazia Therapeutics Ltd ADR (KZIA) Stock Chart
Kazia Therapeutics Ltd ADR (KZIA) has a latest price of $5.31 on Nov 17, 2026, 69.5% below its 52-week high of $17.40. Its price fell 15.3% over the past 12 months. The month-end price fell 94.4% since Nov 2017, a compound annual decline of 27.6%.
Price Chart
From Nov 2017 to Oct 2026, its highest month-end close was $620.00 in Mar 2021 and its lowest $3.59 in Apr 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart KZIA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for KZIA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 62.3%, and over 6 months it fell 56.0%. The month-end price fell 59.5% over the 3 years through Oct 2026, a compound annual decline of 26.0%.
| Period | Change |
|---|---|
| 1 month | -32.4% |
| 3 months | -62.3% |
| 6 months | -56.0% |
| 12 months | -15.3% |
| 12 months, with dividends | -15.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -59.5% | -26.0% |
| 5 years | -98.4% | -56.4% |
| Since Nov 2017 | -94.4% | -27.6% |
Price by Year
Its best calendar year was 2020, when the price rose 99.1%, and its weakest was 2022, when it fell 92.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $8.50 | +23.4% |
| 2025 | $6.89 | -22.1% |
| 2024 | $8.85 | -59.7% |
| 2023 | $21.98 | -28.5% |
| 2022 | $30.75 | -92.7% |
| 2021 | $421.00 | -2.5% |
| 2020 | $432.00 | +99.1% |
| 2019 | $217.00 | +78.6% |
| 2018 | $121.50 | -23.6% |
Trading Range
The price is 39.1% below its 50-day average of $8.71 and 49.7% below its 200-day average of $10.56.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $5.31 | |
| 52-week high | $17.40 | -69.5% |
| 52-week low | $4.86 | +9.3% |
| 50-day average | $8.71 | -39.1% |
| 200-day average | $10.56 | -49.7% |
Price Risk
Over 3 years, its largest fall from a peak was 95.0%.
| Measure | Value |
|---|---|
| 1-year beta | 2.57 |
| Largest fall, 1 year | -68.6% |
| Largest fall, 3 years | -95.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About KZIA
What is KZIA's 1-year price change?
Kazia Therapeutics Ltd ADR's price fell 15.3% over the past 12 months. With dividends included, the 12-month total return was -15.3%.
What is KZIA's 5-year price change?
Kazia Therapeutics Ltd ADR's month-end price fell 98.4% over the 5 years through Oct 2026, a compound annual decline of 56.4%. These figures leave out dividends.
What is KZIA's 52-week high and low?
Kazia Therapeutics Ltd ADR's 52-week high is $17.40 and its 52-week low is $4.86. Its latest price of $5.31 on Nov 17, 2026 is 69.5% below the high.
What is KZIA's beta?
Kazia Therapeutics Ltd ADR's 1-year beta against the S&P 500 is 2.57, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 68.6%.
Is the KZIA chart free?
Yes. Advanced Charting for KZIA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
KZIA pages: Overview, Charting, Financials